Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
Company Supplements Broad RNAi IP Portfolio and Strengthens Growing Position in Oncology
Silence Therapeutics plc announced the issuance of United States patent 7,723,316, titled Compositions and Methods of RNAi Therapeutics For Treatment of Cancer and Other Neovascularization Disease, by the United States Patent and Trademark Office (USPTO). The issued patent, which deepens the Company's diverse portfolio of RNA interference (RNAi) intellectual property, is broadly directed to a double-stranded short interfering RNA (siRNA) sequence that targets vascular endothelial growth factor receptor 2 (VEGFR2).
VEGFR2 has been demonstrated to play an important role in the vasculogenic and angiogenic activities that contribute to the development and progression of tumors associated with a broad range of cancers. The issued subject matter is not limited to the VEGFR2 compositions and also includes methods for reducing tumor growth.
"Silence is compiling a powerful portfolio of intellectual property with value tied to the unique scope of its issued claims and not simply a large number of owned patents. Today's patent issuance fits perfectly with this strategy, as in our opinion, there are few disease targets with IP value comparable to VEGFR2," stated Philip Haworth, Ph.D., chief executive officer of Silence Therapeutics. "With its demonstrated connection to a broad host of cancers, among other disease areas, VEGFR2 is a target that we expect to help drive the expansion of Silence's RNAi therapeutics pipeline. We view today's milestone as more than just another patent issuance; it is a development that significantly enhances the fundamental usefulness and functionality of our growing RNAi IP estate."
Most read news
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

CARBIOS celebrates the groundbreaking of its PET biorecycling plant - CARBIOS’ first plant is also a world first using revolutionary enzymatic depolymerization technology
Diabetes Set to Become Biggest Killer in India, China and Brazil
ProteoNic and Genencor Sign Research Agreement
Multi-drug resistant infections rising in children
Researchers find potential treatment for Huntington's disease - Better understanding of synaptic activity may support 'use it or lose it' hypothesis
American Peptide Company Announces Expansion of Its GMP Manufacturing Facility - Company expands capacity to accommodate large scale peptide production for growing customer base

Mystery of heart repair solved - New mechanism of cell communication found

Liquid crystal liver - First and new realistic 3D model of the liver lobule since the year 1949
